Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric H Rubin

Showing results (31-40 of 66) with videos related to

Pageof 7
Sort By:
Oncogene|April 27, 2004
The topoisomerase I- and p53-binding protein topors is differentially expressed in normal and malignant human tissues and may function as a tumor suppressorAhamed Saleem, Jayeeta Dutta, Diptee Malegaonkar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2006
Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumorsAntoinette R Tan, Dirk F Moore, Manuel Hidalgo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2009
Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumorsAntoinette R Tan, Eric H Rubin, Diana C Walton, et al.
Cancer Research|June 18, 2003
Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecinRajeev Rajendra, Murugesan K Gounder, Ahamed Saleem, et al.
Molecular and Cellular Biology|March 18, 2003
Transcription-dependent degradation of topoisomerase I-DNA covalent complexesShyamal D Desai, Hui Zhang, Alexandra Rodriguez-Bauman, et al.
The Journal of Biological Chemistry|July 13, 2004
Topors functions as an E3 ubiquitin ligase with specific E2 enzymes and ubiquitinates p53Rajeev Rajendra, Diptee Malegaonkar, Pooja Pungaliya, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 3, 2017
Immuno-oncology Clinical Trial Design: Limitations, Challenges, and OpportunitiesChristina S Baik, Eric H Rubin, Patrick M Forde, et al.
Journal for Immunotherapy of Cancer|February 1, 2022
Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumorsRazvan Cristescu, Deepti Aurora-Garg, Andrew Albright, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|December 9, 2003
Development of a bioanalytical liquid chromatography method for quantitation of 9-nitrocamptothecin in human plasmaMurugesan K Gounder, Show-Li Sun, Howard Sands, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2007
Phase I and pharmacokinetic study of imatinib mesylate (Gleevec) and gemcitabine in patients with refractory solid tumorsYaqoob Ali, Yong Lin, Mecide M Gharibo, et al.
Pageof 7

Showing results (31-40 of 66) with videos related to

Sort By:
Pageof 7
Oncogene|April 27, 2004
The topoisomerase I- and p53-binding protein topors is differentially expressed in normal and malignant human tissues and may function as a tumor suppressorAhamed Saleem, Jayeeta Dutta, Diptee Malegaonkar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2006
Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumorsAntoinette R Tan, Dirk F Moore, Manuel Hidalgo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2009
Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumorsAntoinette R Tan, Eric H Rubin, Diana C Walton, et al.
Cancer Research|June 18, 2003
Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecinRajeev Rajendra, Murugesan K Gounder, Ahamed Saleem, et al.
Molecular and Cellular Biology|March 18, 2003
Transcription-dependent degradation of topoisomerase I-DNA covalent complexesShyamal D Desai, Hui Zhang, Alexandra Rodriguez-Bauman, et al.
The Journal of Biological Chemistry|July 13, 2004
Topors functions as an E3 ubiquitin ligase with specific E2 enzymes and ubiquitinates p53Rajeev Rajendra, Diptee Malegaonkar, Pooja Pungaliya, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 3, 2017
Immuno-oncology Clinical Trial Design: Limitations, Challenges, and OpportunitiesChristina S Baik, Eric H Rubin, Patrick M Forde, et al.
Journal for Immunotherapy of Cancer|February 1, 2022
Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumorsRazvan Cristescu, Deepti Aurora-Garg, Andrew Albright, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|December 9, 2003
Development of a bioanalytical liquid chromatography method for quantitation of 9-nitrocamptothecin in human plasmaMurugesan K Gounder, Show-Li Sun, Howard Sands, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2007
Phase I and pharmacokinetic study of imatinib mesylate (Gleevec) and gemcitabine in patients with refractory solid tumorsYaqoob Ali, Yong Lin, Mecide M Gharibo, et al.
Pageof 7